Circulating tumour DNA (ctDNA) to guide adjuvant chemotherapy and surveillance strategies in patients with stage II colon cancer

点击翻译按钮获取中文摘要

This study is attempting to demonstrate that an adjuvant therapy strategy based on ctDNA results will reduce the number of patients with stage II colon cancer receiving adjuvant chemotherapy without compromising recurrence free survival. Prospective multi-centre study enrolling 450 stage II colon cancer patients. Patients will be randomized 2:1 to be treated according to ctDNA results (Arm A, n = 300), or per standard clinical criteria (Arm B, n = 150).